Johnson & Johnson $JNJ Shares Sold by ProShare Advisors LLC

Key Points

• ProShare Advisors LLC reduced its Johnson & Johnson stake by 7.3% in the fourth quarter, selling 110,041 shares and ending with 1,402,778 shares valued at about $290.3 million.
• Analyst sentiment remains broadly positive, with the stock carrying a “Moderate Buy” consensus and an average price target of $253.04. Recent notes included target raises from JPMorgan and Raymond James, while Leerink upgraded J&J to Outperform with a $265 target.
• J&J continues to show solid fundamentals and shareholder returns after reporting Q1 EPS of $2.70 and revenue of $24.06 billion, both ahead of estimates, and raising its quarterly dividend to $1.34 per share.

ProShare Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,402,778 shares of the company's stock after selling 110,041 shares during the quarter. ProShare Advisors LLC owned about 0.06% of Johnson & Johnson worth $290,305,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the third quarter valued at $26,000. Cresta Advisors Ltd. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $26,000. DecisionPoint Financial LLC lifted its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after purchasing an additional 75 shares during the period. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after purchasing an additional 49 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Raymond James Financial lifted their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an "outperform" rating in a report on Wednesday, April 15th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a "hold" rating in a research report on Wednesday, April 15th. Finally, Scotiabank reiterated an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $253.04.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform and raised its price target to $265, citing strong new-drug momentum and improved growth prospects. Article: Is Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?
• Positive Sentiment: J&J’s oncology pipeline received attention after the company presented encouraging early/Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, reinforcing the company’s cancer-treatment growth story. Article: Johnson & Johnson Lung Cancer Data Adds Dimension To Oncology Valuation Story
• Positive Sentiment: Multiple articles highlighted Johnson & Johnson as a strong dividend and “Dogs of the Dow” name, which supports the stock’s defensive appeal for income-focused investors. Article: Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
• Neutral Sentiment: Nanobiotix also said J&J presented Part 1 data from the CONVERGE study, adding more visibility to the company’s oncology collaboration, though the market impact appears limited so far. Article: Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer
• Negative Sentiment: The U.S. Supreme Court declined to hear a challenge to the Medicare drug-price negotiation program, leaving intact a policy that could continue to pressure pricing for Johnson & Johnson’s pharmaceutical business. Article: Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program

Johnson & Johnson Stock Performance

NYSE JNJ opened at $228.80 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The business's 50 day moving average is $234.91 and its two-hundred day moving average is $222.31. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The stock has a market capitalization of $550.76 billion, a price-to-earnings ratio of 26.45, a PEG ratio of 2.22 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is presently 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.